Drug Trial Radar · NCT00851227
Study to Compare Conivaptan in Subjects With Mild & Moderate Liver Impairment Versus Subjects With Normal Liver Function
Last checked: Nov 19, 2026Latest source record: May 2, 2014 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
26
Actual
Start
Feb 2009
Primary completion
Jan 2010
Study completion Jan 2010
Sponsor
- Lead sponsor
- Cumberland PharmaceuticalsIndustry
- Sponsor type
- Industry
- First posted
- Feb 25, 2009
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Non randomized
- Model
- Parallel
- Masking
- None
- Who can join
- All sexes, from 30 years, up to 70 years
- Healthy volunteers
- Yes
Summary
As written by the sponsor on the registry.
A study to compare a 48-hour continuous infusion of conivaptan in subjects with mild and moderate liver impairment versus subjects with normal liver function
Conditions
- Liver Disease
- Hyponatremia
Interventions
conivaptan hydrochlorideDrug
intravenous
Primary outcomes
What the sponsor says the trial is designed to measure.
- Measure PK and protein binding of conivaptanTime frame: 5 days
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Site not named
Miami, Florida
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.